Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Autor: Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik Hellem, Beksac, Meral, Hájek, Roman, Weisel, Katja Christina, Goldscmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agniezka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Thomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, Vincent

Publikováno v: Dimopoulos, Meletios A. Gay, Francesca Schjesvold, Fredrik Hellem Beksac, Meral Hájek, Roman Weisel, Katja Christina Goldscmidt, Hartmut Maisnar, Vladimir Moreau, Philippe Min, Chang Ki Pluta, Agniezka Chng, Wee-Joo Kaiser, Martin Zweegman, Sonja Mateos, Maria Victoria Spencer, Andrew Iida, Shinsuke Morgan, Gareth Suryanarayan, Kaveri Teng, Zhaoyang Skacel, Thomas Palumbo, Antonio Dash, Ajeeta B. Gupta, Neeraj Labotka, Richard Rajkumar, Vincent . Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. 2018, 393(10168), 253-264
The Lancet

Externí odkaz: http://hdl.handle.net/10852/72958
https://www.duo.uio.no/bitstream/handle/10852/72958/2/Dimopoulos-Rajkumar%2BMM3%2BLancet%2Bmanuscript%2Brevised%2B16Nov18_authors.pdf